Drug Trial Radar · NCT01986101
A Phase III Study of SM-13496 in Patients With Bipolar I Depression.
Last checked: Nov 20, 2026Latest source record: Apr 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
525
Actual
Start
Feb 19, 2014
Primary completion
Feb 1, 2017
Study completion Feb 16, 2017
Sponsor
- Lead sponsor
- Sumitomo Pharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 18, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with Bipolar I Depression.
Conditions
- Bipolar Depression
Interventions
PlaceboDrug
Placebo comparator
SM-13496Drug
SM-13496 20mg for Days 1-7 and beginning Day 8 flexibly dosed 20-60 mg/day for Weeks 2-6
SM-13496Drug
SM-13496 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6, 80 mg/day on Day 7 and beginning Day 8 flexibly dosed 80-120 mg/day for Weeks 2-6
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6Time frame: Baseline to 6 weeks
Locations
8 sites in 8 countries. Site status is shown where the registry gives one.
Japan 76 sites
Tokyo, Japan
Lithuania 3 sites
Kaunas, Lithuania
Malaysia 5 sites
Kuala Lumpur, Malaysia
Philippines 4 sites
Manila, Philippines
Russia 19 sites
Moscow, Russia
Slovakia 5 sites
Žilina, Slovakia
Taiwan 7 sites
Taipei, Taiwan
Ukraine 9 sites
Kiev, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.